In a phase 2 clinical trial, soluble lymphocyte-activation gene 3 (LAG-3) as a potential treatment for non-small cell lung cancer (NSCLC) performed well across all levels of programmed cell death-ligand 1 (PD-L1) expression.

“We observed a very encouraging response rate. Responses were seen across PD-L1 status,” said Wade Iams, MD, Vanderbilt...